Related Experiment Video

Updated: Aug 19, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Carbamazepine in two pregnancies

E P Hicks

    Clinical and Experimental Neurology
    |January 1, 1979
    PubMed

    2 patients with epilepsy in pregnancy are described. Both received carbamazepine prior to conception, and during the greater portion of the first trimester. Both had partial and generalised epilepsy of late onset. Case 1 resulted in stillbirth at 25 weeks' gestation. The malformations included closely set eyes, atresia of multiple hollow viscera, and non-fusion of the mandible without hare lip or cleft palate. A possible interaction with a compound analgesic is discussed. Case 2 resulted in a normal baby. The literature, although favouring carbamazepine in pregnancy, is not yet sufficiently decisive to indicate a clear preference between no treatment and carbamazepine with carefully monitored serum levels for epilepsy in pregnancy. This study emphasises the need for continued pooling of data, and for added caution when there is a history of fetal malformation or obstetric problems. The teratogenicity of carbamazepine is neither confirmed nor denied by this limited study.

    More Related Videos

    Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale07:35

    Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

    Published on: July 8, 2025

    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

    Published on: February 28, 2025

    Related Concept Videos

    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
    Antiepileptic Drugs: Sodium Channel Blockers01:08

    Antiepileptic Drugs: Sodium Channel Blockers

    Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
    Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
    Among the most commonly prescribed antiepileptic drugs are...
    Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

    Antiepileptic Drugs: GABAergic Pathway Potentiators

    γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
    The key GABA pathway potentiators used in epilepsy management are as follows.
    Benzodiazepines are a well-known class of drugs used for their...
    Antiepileptic Drugs: Calcium Channel Blockers01:17

    Antiepileptic Drugs: Calcium Channel Blockers

    Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
    Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Antiepileptic Drugs: Potassium Channel Activators01:20

    Antiepileptic Drugs: Potassium Channel Activators

    Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
    Ezogabine has gained approval as an adjunctive treatment...